Zevra’s Miplyffa Wins First-Ever US Approval, But In Combination With Off-Label Miglustat
Drug’s List Price Is $1m Per Year On Average
Miplyffa (arimoclomol) was approved for Niemann-Pick disease type C when administered with another high-priced drug used off label as standard of care for about 80% of NPC patients.
